Source of Support: None, Conflict of Interest: None
Check
Vincristine, cyclophosphamide and methotrexate combination chemotherapy was administered on an outpatient basis to 25 patients of advanced bronchogenic carcinoma. The overall median survival of the patients was 30 weeks, patients of small cell carcinoma had a median survival of 23.5 weeks and it was 25 weeks in cases of patients of non-small cell carcinoma. Eleven patients (44%) survived for six months or more, five patients (20%) survived for one year or more and two patients (8%) survived for two years or more. The drug combination is relatively cheap and had no major side effects.
